Kirill Prusakov

Mr. Kirill Prusakov

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
OMOlga V. Morozova
Olga V. Morozova
EPElizaveta R Pavlova
Elizaveta R Pavlova
DBDmitry Bagrov
Dmitry Bagrov
NBNikolay A Barinov
Nikolay A Barinov
KPKirill Prusakov
Kirill Prusakov
DKDmitry Klinov
Dmitry Klinov
Purpose: To develop a general method for NP fabrication from various proteins with maintenance of biological activity. Methods: A novel general approach for producing protein nanoparticles (NP) by nanoprecipitation of the protein solutions in 1,1,1,3,3,3-hexafluoroisopropanol is described. Protein NP sizes and shapes were analyzed by dynamic light scattering, scanning electron and atomic force microscopy (SEM and AFM). Chemical composition of the NP was confirmed using ultraviolet (UV) spectroscopy, energy-dispersive X-ray spectroscopy (EDX) and circular dichroism (CD). Biological properties of the NP were analyzed in ELISA, immunofluorescent analysis and lysozyme activity assay. Results: Water-insoluble NP were constructed from globular (bovine serum albumin (BSA), lysozyme, immunoglobulins), fibrillar (fibrinogen) proteins and linear polylysines by means of nanoprecipitation of protein solutions in fluoroalcohols. AFM and SEM revealed NP sizes of 20–250 nm. The NP chemical structure was confirmed by UV spectroscopy, protease digestion and EDX spectroscopy. CD spectra revealed a stable secondary structure of proteins in NP. The UV spectra, microscopy and SDS-PAA gel electrophoresis (PAGE) proved the NP stability at +4°C for 7 months. Co-precipitation of proteins with fluorophores or nanoprecipitation of pre-labeled BSA resulted in fluorescent NP that retained antigenic structures as shown by their binding with specific antibodies. Moreover, NP from monoclonal antibodies could bind with the hepatitis B virus antigen S. Besides that, lysozyme NP could digest bacterial cellular walls. Conclusion: Thus, the water-insoluble, stable protein NP were produced by nanoprecipitation without cross-linking and retained ligand-binding and enzymatic activities.

26 October 2015 in Peptide Science
Verified
Journal Article
Closed access
PDF file
DBDmitry Bagrov
Dmitry Bagrov
YGYuliya Gazizova
Yuliya Gazizova
VPVictor Podgorsky
Victor Podgorsky
IUIgor Udovichenko
Igor Udovichenko
ADAlexey Danilkovich
Alexey Danilkovich
DKDmitry Klinov
Dmitry Klinov

1 November 2016 in Journal of Luminescence
Verified
Journal Article
Closed access
FTFeruza T. Tuyakova
Feruza T. Tuyakova
EOEkaterina A. Obraztsova
Ekaterina A. Obraztsova
EKEvgeny V. Korostylev
Evgeny V. Korostylev
DKDmitry V. Klinov
Dmitry V. Klinov
KPKirill Prusakov
Kirill Prusakov
AOAlexander N. Obraztsov
Alexander N. Obraztsov

1 July 2016 in Infection and Immunity
Verified
Journal Article
Open access
PDF file
PBPavel Bobrovsky
Pavel Bobrovsky
Valentin ManuveraValentin Manuvera
Valentin Manuvera
NPNadezhda Polina
Nadezhda Polina
OPOleg Podgorny
Oleg Podgorny
KPKirill Prusakov
Kirill Prusakov
VLVassili Lazarev
Vassili Lazarev
Peptidoglycan recognition proteins (PGLYRPs) are innate immune components that recognize the peptidoglycan and lipopolysaccharides of bacteria and exhibit antibacterial activity. Recently, the obligate intracellular parasite Chlamydia trachomatis was shown to have peptidoglycan. However, the antichlamydial activity of PGLYRPs has not yet been demonstrated. The aim of our study was to test whether PGLYRPs exhibit antibacterial activity against C. trachomatis . Thus, we cloned the regions containing the human Pglyrp1 , Pglyrp2 , Pglyrp3 , and Pglyrp4 genes for subsequent expression in human cell lines. We obtained stable HeLa cell lines that secrete recombinant human PGLYRPs into culture medium. We also generated purified recombinant PGLYRP1, -2, and -4 and confirmed their activities against Gram-positive ( Bacillus subtilis ) and Gram-negative ( Escherichia coli ) bacteria. Furthermore, we examined the activities of recombinant PGLYRPs against C. trachomatis and determined their MICs. We also observed a decrease in the infectious ability of chlamydial elementary bodies in the next generation after a single exposure to PGLYRPs. Finally, we demonstrated that PGLYRPs attach to C. trachomatis elementary bodies and activate the expression of the chlamydial two-component stress response system. Thus, PGLYRPs inhibit the development of chlamydial infection.

20 October 2016 in Nucleic Acid Therapeutics
Verified
Journal Article
Closed access
MPMaria Prokofjeva
Maria Prokofjeva
Vladimir Borisovich TsvetkovVladimir Borisovich Tsvetkov
Vladimir Borisovich Tsvetkov
DBDmitry Basmanov
Dmitry Basmanov
Anna VarizhukAnna Varizhuk
Anna Varizhuk
MLMaria Lagarkova
Maria Lagarkova
SMSergey N. Mikhailov
Sergey N. Mikhailov
New natural and chemically modified DNA aptamers that inhibit HIV-1 activity at submicromolar concentrations (presumably via preventing viral entry into target cells) are reported. The new DNA aptamers were developed based on known intramolecular G-quadruplexes (G4s) that were functionally unrelated to HIV inhibition [the thrombin-binding aptamer and the fragment of the human oncogene promoter ( Bcl2 )]. The majority of previously described DNA inhibitors of HIV infection adopt intermolecular structures, and thus their folding variability represents an obvious disadvantage. Intramolecular architectures refold correctly after denaturation and are generally easier to handle. However, whether the G4 topology or other factors account for the anti-HIV activity of our aptamers is unknown. The impact of chemical modification (thiophosphoryl internucleotide linkages) on aptamer activity is discussed. The exact secondary structures of the active compounds and further elucidation of their mechanisms of action hopefully will be the subjects of future studies.

1 July 2019 in International Journal of Adhesion and Adhesives
Verified
Journal Article
Closed access
OMOlga V. Morozova
Olga V. Morozova
OLOlga Alexandrovna Levchenko
Olga Alexandrovna Levchenko
ZCZlata A. Cherpakova
Zlata A. Cherpakova
VPValery V. Prokhorov
Valery V. Prokhorov
NBNikolay A. Barinov
Nikolay A. Barinov
DKDmitry V. Klinov
Dmitry V. Klinov